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Abstract
Inflammatory bowel diseases (IBD) are chronic diseases 
with a relapsing-remitting disease course necessitating 
lifelong treatment. However, non-adherence has been 
reported in over 40% of patients, especially those 
in remission taking maintenance therapies for IBD. 
The economical impact of non-adherence to medical 
therapy including absenteeism, hospitalization risk, 
and the health care costs in chronic conditions, is 
enormous. The causes of medication non-adherence 
are complex, where the patient-doctor relationship, 
treatment regimen, and other disease-related factors 
play key roles. Moreover, subjective assessment might 
underestimate adherence. Poor adherence may result 
in more frequent relapses, a disabling disease course, 
in ulcerative colitis, and an increased risk for colorectal 
cancer. Improving medication adherence in patients is 
an important challenge for physicians. Understanding 
the different patient types, the reasons given by patients 
for non-adherence, simpler and more convenient dosage 
regimens, dynamic communication within the health 
care team, a self-management package incorporating 
enhanced patient education and physician-patient 
interaction, and identifying the predictors of non-
adherence will help devise suitable plans to optimize 
patient adherence. This editorial summarizes the 
available literature on frequency, predictors, clinical 
consequences, and strategies for improving medical 
adherence in patients with IBD.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a multifactorial entity 
with both genetic and environmental factors contributing 
to disease pathogenesis[1]. Worldwide, the incidence rates 
for IBD vary from 0.5 to 24.5 per 100 000 person-years[2], 
with the majority of  patients being disabled during various 
parts of  their lives. This characteristic may also suggest 
poor adherence (i.e. a percentage of  the prescribed doses 
is not taken) outside the clinical trial settings[3-5].
Treatment of  IBD can involve several medications 
with varying regimens, dietary modifications, and po-
tentially, surgery, depending on symptoms, severity of  
illness, and response to treatment. Adherence to the phar-
macological treatment is a complex process, where the 
doctor-patient relationship, treatment regimen and other 
disease-related factors play key roles. The undesirable side 
effects of  some medications (e.g. weight gain, cushingoid 
appearance, and immune suppression) and the complex 
treatment regimens for IBD patients (e.g. varying dosing 
schedules and pill quantities for each medication) are likely 
to disrupt adherence and the effective management of  this 
condition. These data are consistent with the hypothesis 
that many patients engage in an implicit cost-benefit analy-
sis in which beliefs about the necessity of  their medication 
are weighed against concerns about the potential adverse 
effects of  taking it, and that these beliefs are related to 
medication adherence, as in other chronic conditions[6]. 
This scenario has been also proven in patients with IBD 
in a very recent paper[7]. In contrast, the impact of  medica-
tion non-adherence on the hospitalization risk and health 
care costs in chronic conditions (e.g. diabetes, hyperten-
sion, and congestive hearth failure) is enormous[8]. It has 
been estimated to cost as much as $100 billion in the US 
annually, and accounts for 10% of  all hospital admissions. 
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However, there are no studies that directly assess the costs 
associated with non-adherence in patients with IBD. Re-
cently, it has been estimated in the UK that relapse was 
associated with a two- to threefold increase in the costs 
for those who did not require hospital care and a 20-fold 
increase for those who were hospitalized[9].
Research on adherence in IBD is limited. Studies in 
adults have revealed medication non-adherence rates 
ranging from 35% to 45%[3,5,10]. Unfortunately, most of  
these studies used different, unimodal indirect assess-
ment methods including non-standardized self-report 
questionnaires, non-standardized patient/parent inter-
views, pill counts, pharmacy records, and measurements 
of  health outcomes. A drawback of  this method is that 
it can overestimate adherence, and its accuracy depends 
on the patient’s cognitive abilities, the honesty of  replies, 
as well as the interviewer’s correct interpretation of  re-
sponses. The patient may forget doses taken or missed. 
Prescription refills are also considered questionable for 
assessing dosing compliance because they provide no in-
formation on timing or quantity of  pills ingested. In ad-
dition, pill counts are often erroneous because patients 
do not always return bottles with leftover pills. Thus, 
until now, the methods for assessing compliance have 
varied in terms of  prospective versus retrospective or 
objective versus subjective measurement, target behaviour 
assessed (e.g. consumption of  medication and refill of  
prescription), medication assessed, and method of  as-
sessment. This variability resulted in different estimates 
of  the prevalence of  non-adherence and diminished 
generalizability and the validity of  data. Furthermore, 
these studies were limited by potential response bias in 
the self-report measures or behavioural manipulation, 
such as discarding pills to influence pill count data[11]. 
In general, direct methods for measuring medication 
adherence include drug concentration monitoring through 
blood and urine assays. This strategy is expensive and 
inconvenient for patients, and, moreover, only a limited 
number of  drugs can be monitored in this manner. The 
bioavailability and completeness of  absorption of  various 
drugs, as well as the rate of  metabolism and excretion, are 
factors that make it difficult to correlate drug concentra-
tions in blood or urine with adherence. The ability of  
direct methods to identify non-adherence also depends on 
the accuracy of  the test and the degree to which the pa-
tient was non-adherent before the urine or blood sample 
was taken. Drug concentration monitoring can also be 
misleading because most drugs are rapidly absorbed fol-
lowing administration. Thus, even if  numerous doses were 
omitted, yet a few doses were taken immediately prior to 
the blood test, the results would show the presence of  a 
moderate amount of  drug, or vice versa. 
In IBD, bioassays measuring 6-thioguanine nucle-
otide (6-TGN) and 6-methylmercaptopurine nucleotide 
(6-MMPN) levels have been suggested as potentially use-
ful objective adherence markers for 6-mercaptopurine 
(6-MP)/azathioprine (AZA)[11,12]. However, they have 
not been validated against traditional measures of  adher-
ence. Moreover, like other bioassays, they are subject to 
pharmacokinetic variation in absorption, metabolism, 
and excretion. Despite their limitations, bioassays provide 
key adherence data in that they can confirm ingestion. 
Non-therapeutic metabolite levels can suggest either non-
adherence or pharmacokinetic influence, or both; cases 
where both 6-TGN and 6-MMPN levels are subtherapeu-
tic/unquantifiable are likely to indicate non-adherence. 
Thus, although there is no gold standard in adherence 
assessment, and limitations exist with any measure of  ad-
herence, both behavioural and biological measures offer 
unique data that could be used to better understand non-
adherence. Moreover, determining the most advantageous 
approach to assessing adherence is critical to the clinical 
care of  these patients. This editorial summarizes the avail-
able literature on frequency, predictors, clinical conse-
quences, and strategies for improving medical adherence 
in patients with IBD.
PREVALENCE OF NON-ADHERENCE IN 
IBD
In normal clinical practice, adult studies have revealed 
medication non-adherence prevalence rates ranging from 
35% to 72%[3,5,10,13,14]. For example a cross-sectional study 
of  US outpatients with quiescent ulcerative colitis (UC) 
found that only 40% were adherent to maintenance me-
salazine (mesalamine) therapy[3]. In the UK, approximately 
15% of  patients fail to even redeem prescriptions at the 
pharmacy[15]. Moreover, treatment non-adherence rates 
might vary considerably between countries. In Europe, a 
survey of  203 IBD patients revealed self-reported non-
adherence rates ranging from 13% in France, to 26% in 
Italy, 33% in the UK and 46% in Germany. The overall 
non-adherence rate was 29% across Europe[4], where non-
adherence was defined as taking < 80% of  prescribed 
medication. Similarly high rates of  non-adherence were 
reported from Eastern Europe. Overall intentional non-
adherence was reported by 38.9% of  patients, and 18.6% 
of  the patients at least once discontinued the treatment[5]. 
In a Canadian study, UC diagnosis was associated with 
higher risk of  non-adherence (OR: 4.42)[16].
Significant differences may exist in children and ado-
lescents, given the complex developmental challenges 
unique to childhood and adolescence, including the matu-
ration of  cognitive and behavioral patterns (e.g. health 
beliefs) that affect self-management. However, only a 
few studies have examined adherence rates in pediatric 
IBD, with the results indicating the prevalence of  non-
adherence ranging from 50% to 66%[17,18]. Moreover, 
special attention should be paid to the method of  assess-
ment, because significant differences may be present in 
objective methods versus subjective self-report methods. 
In a recent paper, Hommel et al[11] reported an objective 
non-adherence frequency of  38% for 6-MP/AZA and 
49% for 5-ASA medications, while the subjective non-
adherence frequency was reported to be as low as 6% for 
6-MP/AZA and 3% for 5-ASA. In contrast, in a prospec-
tive, single-center study from Germany[19] both objective 
(9.2%) and self-reported (7.1%) non-adherence rates were 
low in 65 adult Crohn’s disease (CD) patients.
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PREDICTIVE FACTORS FOR NON 
ADHERENCE AND CLINICAL 
CONSEQUENCES 
Gender
Conflicting data are available on the role of  gender in 
predicting non-adherence to medical therapy. Kane et al[3] 
and Mantzaris et al[20] related poor adherence with the male 
gender. In the study by Kane et al[3] non-adherent patients 
were statistically more likely to be males (67% vs 52% in 
adherent patients). Gender interactions also proved rel-
evant in a recent population-based study, in which young 
females proved to be less adherent than males[17], while 
other studies could not find a significant difference[5]. In 
addition there may be different factors affecting medica-
tion adherence in men and women. In the study by Ediger 
et al[16] a diagnosis of  ulcerative colitis (vs Crohn’s disease) 
having high scores on the Obstacles to Medication Use 
Scale and a low level of  the personality trait of  agree-
ableness, were important predictors of  low adherence in 
males. For women, important predictors of  low adherence 
included an age younger than 30 years, having high scores 
on the Obstacles to Medication Use Scale, and having a 
low level of  the personality trait of  agreeableness. Immu-
nosuppressant use was associated with high adherence in 
women. 
Similarly, data are conflicting with regards to marital 
status, type of  education, employment status, or type of  
disease. A higher education level and full time employ-
ment was also associated with a non-adherent patient 
behavior in some[5,16,21], but not all, studies[14].
Age and disease duration 
Age seems to be an important factor, as younger patients 
tend to be less adherent than older patients[10,18]. In a re-
cent Italian study[22] non-adherence was 43% in patients 
< 40 years old compared to 34% in those older than 40 
years (P = 0.041, OR: 1.5, CI: 1.01-2.13). Recently, diag-
nosis and disease duration shorter than 5 years was also 
associated with significantly worse adherence (24% of  
the patients) than a longer-standing disease (15% of  the 
patients; P = 0.001, OR: 2.1, CI: 1.30-3.39) in the same 
study. Moreover, non-adherence increased to 75% when 
both age (< 40 years) and disease duration (< 5 years) 
were considered. This may have to do with the fact that 
IBD primarily affects young individuals with greater per-
sonal and social goals, being busy at work, and having 
some degree of  rebelliousness, but it may also be that a 
younger age is associated with a more recent diagnosis, 
with less experience with the burden of  relapse or surgery. 
This was, however, not a universal finding[5].
Phenotype, disease activity and surgery
In UC, Kane et al[3] reported by means of  univariate 
analysis, that male gender, being without a relationship 
partner, left-sided disease, and a history of  more than four 
concomitant medications, were negatively associated with 
adherence. Conversely, being married, having a recent 
colonoscopy, and a greater extent of  disease supported 
adherence. A UK-based cross-sectional study, using data 
extracted from general practitioner (GP) clinical records, 
examined the usage of  long-term aminosalicylate therapy 
in patients with UC[13]. It was found that 38% of  the pa-
tients with extensive colitis, 37% of  the patients with left-
sided colitis and 46% of  those with proctitis did not take 
medications for maintenance therapy. This was not, how-
ever, confirmed in all studies[5]. 
An association between medical adherence and com-
plicated disease course in CD was reported by Spanish 
authors[14]. Better adherence was significantly associated 
with a more complicated disease course (steroid depen-
dency, steroid refractoriness, need for infliximab treat-
ment, hospitalization, or surgery) in patients with short 
disease duration. Similarly, in a recent Hungarian study[23], 
a higher number of  previous surgeries was associated with 
improved self-reported adherence in patients with CD.
Active disease was associated with higher adherence, 
even if  steroids were included in the treatment regimen 
in both CD and UC[10]. In contrast, other studies re-
ported low adherence rates after long-term remission[3,22]. 
Very high non-adherence rates (74.3%) were reported 
for azathioprine in CD patients who were in long-term (> 
48 mo) clinical remission[20]. 
Moreover, a direct association between adherence 
and risk of  relapse was reported in UC. Kane et al[24] pro-
spectively studied the risk factors associated with relapse 
among 99 patients who were in remission for more than 
six months and prescribed 5-ASA maintenance therapy. 
The clinical recurrence of  UC was defined as four or 
more bowel movements per day. At a 12-mo follow-up, 19 
of  86 patients had recurrent disease, 13 (68%) of  whom 
were non-adherent. Patients who were non- adherent with 
medication had a greater risk of  recurrence than adherent 
patients (OR: 5.5, 95% CI: 2.3-13). A Kaplan-Meier curve 
constructed to compare outcomes stratified by adherence 
status for 24 mo also showed that UC patients adherent to 
their 5-ASA therapy had a significantly greater chance of  
remaining in remission than those who were non-adherent 
(89% vs 39%; P = 0.001).
Drug type and dosing regimes 
Non-adherence to therapy might also be due to the drug 
formulation causing discomfort (difficulty in swallowing 
tablets or using enemas) or side effects (pain, abdominal 
distension, or difficulty in retaining enemas). Most studies 
are consistent in finding that topical therapy with enemas, 
suppositories or foams is more likely to be associated with 
non-adherence than oral therapy. In an Italian study[22], 
topical therapy with enemas was associated with signifi-
cantly more non-adherence (68% of  users) than oral 
therapy (40% of  users; P = 0.001, OR: 0.25, CI: 0.11-0.60). 
Similarly, analyzing a national prescription-based database 
also showed that overall adherence to mesalazine was un-
expectedly low and the rectal formulation was among the 
factors influencing non-adherence[25]. Enemas were judged 
difficult to use, painful or to cause bloating, and were dif-
ficult to manage during working hours. 
The association between the type of  oral medications 
and non-adherence is more controversial. The undesirable 
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side effects of  some medications (e.g. weight gain, cushin-
goid appearance, or immune suppression) and the com-
plex treatment regimens for IBD patients (e.g. varying dos-
ing schedules and pill quantities for each medication) are 
likely to disrupt adherence and effective management of  
this condition. Interestingly, some studies did not report 
a direct association. For example, in the study by Cervený 
et al[5], the non-adherence rate at any time point was 40% 
on aminosalicylates, 29% in patients on systemic steroids, 
and 31% in patients on immunosuppressants in CD. Simi-
lar data were reported in UC, supporting the notion that 
adherence is influenced by multiple parallel factors, includ-
ing gender, age, disease activity, and so on. Interestingly, 
the same study, using a factor analysis, reported a strong 
influence of  adverse drug effects on adherence. Intention-
al non-adherent behavior due to adverse drug effects was 
the second most common cause reported during a patient 
interview. In addition, adverse drug effects were inde-
pendently proven by factor analysis to affect a patient’s 
confidence in treatment. 
Reasons for non-adherence to oral therapy include 
multiple daily doses and a high number of  concomitant 
medications. In the study by Kane et al[3], besides being 
males, single, and having left-sided disease, non-adherent 
patients were statistically more likely to be taking four or 
more concomitant medications (60% vs 40%). Similarly, in 
the study of  Shale and Riley[21], in addition to being young, 
having education beyond the age of  16 years and being in 
full-time employment, being prescribed a 3-times-a-day 
regimen was identified as predictor for non-adherence. 
The need to take medicine during working hours (P = 
0.001, OR: 3.5, 95% CI: 2.27-5.26), and multiple daily 
doses (P = 0.045, OR: 2.8, 95% CI: 0.99-7.70) were sig-
nificantly associated with non-adherence in adults[22], 
which was also confirmed by other studies[20,21]. Similarly, 
adolescents whose regimen involved more than one daily 
medication administration had more adherence barriers[26]. 
In addition, lack of  time and medication side effects 
were also commonly reported barriers. Other adolescent-
reported barriers included missing medication due to feel-
ing well or discontinuing medication based on the belief  
that the medication was not working. In contrast, a recent 
retrospective cohort study suggests that adherence in UC 
patients is independent of  drug formulation[27]. Magowan 
et al[27] used records from multiple US health plans to com-
pare the refill prescription profiles of  1680 UC patients 
who had initiated 5-ASA therapy with one of  four formu-
lations: delayed-release mesalamine (Asacol), controlled-
release mesalamine (Pentasa), sulfasalazine (Azulfidine), 
or balsalazide (Colazal). Upon initiation of  treatment, 
the median daily dose and respective tablet/capsule load 
were 2.4 g (6 tablets) for delayed-release mesalamine, 4.0 g 
(16 capsules) for controlled-release mesalamine, 2.0 g 
(4 tablets) for sulfasalazine, and 6.75 g (9 capsules) for 
balsalazide. Comparison of  the refill profiles over 12 mo, 
however, indicated that adherence in these patients was 
not affected by formulation type and/or dose regimen.
The use of  once-daily treatment for improving medi-
cal compliance is further supported by a recent rand-
omized, multicentre, investigator-blinded study of  362 
patients who were randomised to receive mesalazine 
granules (Pentasa®) 2 g once daily or 1 g twice daily. It 
showed an 11.9% greater remission rate at one year (73.8% 
vs 63.6%, respectively) in the single daily dose group[28]. 
Patient questionnaires showed significantly greater self-
reported compliance (P < 0.05) and acceptability (P < 
0.001) in the once-daily group. High compliance rates 
were reported for the once-daily MMX mesalazine and 
Salofalk® granules[29,30]; therefore the effect is likely to be 
generic rather than compound-specific. Thus, new mesala-
zine formulations offer a simplified dose regime, resulting 
in presumably improved long-term compliance that can 
be considered an important advantage in the management 
of  UC patients. 
Patient-doctor relationship 
The partnership between patient and the treating physi-
cian is of  utmost importance in determining medical 
adherence, where effective patient-physician dialog is 
central to promoting patient adherence[22]. Studies have 
also shown that the interaction between the patient and 
the physician has a huge impact on health outcomes 
and costs. Both the quality and quantity of  the visits are 
important. Sewitch et al[10] found an increased risk of  
intentional non-adherence to be associated with being 
treated by the same physician for more than one year, 
not scheduling another appointment, and greater total 
discordance between the patient and the physician. Simi-
larly, a higher degree of  intentional non-adherence in the 
study by López San Román et al[31] was associated with 
greater patient depression and patient-physician discord. 
Patients trusted their physician less, and considered 
themselves to be less informed about their treatment. 
A direct association between the total number of  
health care visits and medical adherence was proven in 
children with CD[18]. In addition, patients under specialist 
care were significantly more likely to be taking an ami-
nosalicylate than those definitely discharged to general 
practitioner’s care in adults with UC[13]. In contrast, how-
ever, a European cohort showed no correlation between 
the number of  times an IBD patient had seen the physi-
cian and self-reported medication adherence rates[4]. 
STRATEGIES TO IMPROVE ADHERENCE 
A large body of  evidence supports the key role of  the 
physician-patient relationship in achieving higher patient 
medication-adherence rates. Psychology literature points 
out to using COPE principles as a way for physicians to 
improve their relationship with patients and optimize 
patient adherence to their medication. The COPE 
principles encompass the following: communicate with 
patients; obtain patient’s commitment to therapeutic 
objectives; promote emotional/psychological/physical 
support as necessary; educate the patient and their family. 
In addition, trust in the physician and continuity of  care 
by the same doctor are also important to patients.
In the everyday practice, the physician’s willingness to 
allow patients to contribute input and become involved 
in their illness during the medical visits was suggested to 
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facilitate treatment decisions that are meaningful to both 
parties[32]. The consultation style adopted by the physi-
cian is also an important factor in building the physician-
patient relationship. Indeed, when physicians adopted a 
mutual, co-operative relationship, and exhibited less con-
trol dominance, a reported increase in patient adherence 
and satisfaction was observed. 
During consultations, all factors affecting adher-
ence need to be explored, including the patient’s level of  
knowledge, belief  systems and support environment, for 
example their network of  family and friends.
Written and oral education (on the disease, manage-
ment algorithm and medications) has been shown to 
increase adherence by approximately 6%-25%[33]. Written 
information is more effective when verbally reinforced. 
In addition, a study of  69 patients with IBD demon-
strated improved knowledge, patient satisfaction, and a 
positive trend towards greater adherence in patients who 
had undertaken the IBD education program (consisting 
of  pamphlets and ad hoc physician education), which is 
the standard of  care in many referral centers, compared 
with patients who received standard care[34]. 
Guided self-management involving the provision of  
a shared set of  guidelines containing action plans for the 
prevention of  disease activity and/or symptom relief, 
have been used in the management of  many chronic 
illnesses. A randomized, controlled study evaluating 
guided self-management programs in patients with IBD 
has demonstrated, a reduction in hospital visits without 
an increase in morbidity and greater confidence in the 
patient’s ability to cope with IBD[35]. Further studies are 
needed in order to assess whether such interventions will 
improve adherence to medication and clinical outcomes 
in patients with IBD. Furthermore, a special form of  
patient education could be successfully implemented us-
ing an internet-based patient education platform, as sug-
gested by Elkjaer et al[36].
Another approach that could be used to optimize 
patient adherence involves individualized therapy, where 
physicians review the patient’s disease and therapeutic 
history, and identify which treatment(s) were effective/
ineffective in the past to avoid prescribing the same un-
successful medication. Simplification of  treatment (e.g. 
reduced dosing frequency and the use of  long-acting 
agents) and avoidance of  unnecessary multiple concomi-
tant medications is preferable, where feasible, and are as-
sociated with better adherence and improved clinical out-
come[3,21,24]. Furthermore, this patient review process could 
also provide predictive information on medication non-
adherence behavior, and thus help identify those patients 
at high risk who might require longer consultation slots 
than those at low risk. Patients could also be prompted to 
take their medications via simple pill-taking cues, such as 
placing pills close to something they use daily, for example 
the toothpaste, breakfast table, glasses/contact lenses 
case, and so on. In addition, telephone support, postal 
reminders, and setting alarms on watches/mobile phones 
have been suggested. Nevertheless, combining education 
and behavioral interventions has been suggested to be the 
most effective approach to improving adherence.
CONCLUSION
Non-adherence is common in IBD and has been reported 
in 40%-60% of  patients, especially those in remission and 
taking maintenance therapies for IBD. The economical 
impact of  medication non-adherence, including absentee-
ism, hospitalization risk, and health care costs in chronic 
conditions, is enormous. The causes of  medication non-
adherence are multi-factorial, including forgetfulness, gen-
der, new diagnosis, disease phenotype, patient-physician 
relationship, complicated dosing regimens, side-effect pro-
file of  the drugs, and treatment delivery methods. The as-
sociated factors may vary in each country because of  the 
difference in the healthcare systems and the population. 
Moreover, a gold standard method to estimate the preva-
lence of  non-adherence does not exist. Subjective assess-
ment may underestimate adherence, while recent episodes 
of  non-adherence may result in high non-adherence rates 
if  measured by direct methods (e.g. drug concentration 
monitoring using blood and urine assays). Moreover, this 
latter strategy is expensive and inconvenient for patients, 
and only a limited number of  drugs can be monitored 
in this way. Poor adherence may result in more frequent 
relapses, disabling disease course, and in ulcerative colitis, 
in increased risk for colorectal cancer. Improving medica-
tion adherence in patients is an important challenge for 
physicians. Understanding the different patient types, the 
reasons given by patients for non-adherence, simpler and 
more convenient dose regimens, dynamic communica-
tion within the healthcare team, self-management package 
incorporating enhanced patient education and physician-
patient interaction and identifying the predictors of  non-
adherence, will help devise suitable plans to optimize 
patient adherence. 
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